ARS Pharmaceuticals, Inc. — Director's Dealing 2025

Jun 27, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2025-06-25

Reporting Person: Shah Pratik (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-06-25	Stock Option (right to buy)	$17.26	A	30000	Acquired	2035-06-24	Common Stock (30000)	Direct

Footnotes

F1: The shares subject to the option will vest in full on the earlier of June 25, 2026 or the date of the Issuer's 2026 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.